16 December 2025
Sidley Represents Immunovant in US$550 Million Offering
Advising firms
Deal team
14 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Frank Rahmani Lead | Sidley | Not stated | Capital Markets, Emerging Companies and Venture Capital | Not stated |
| Istvan Hajdu Lead | Sidley | Not stated | Capital Markets, Emerging Companies and Venture Capital | Not stated |
| Carlton Fleming | Sidley | Not stated | Capital Markets | Not stated |
| Katie Klaben | Sidley | Not stated | Capital Markets | Not stated |
| Jen Greenberg | Sidley | Not stated | Capital Markets | Not stated |
| Emily Chazen | Sidley | Not stated | M&A | Not stated |
| Torrey Cope | Sidley | Not stated | Food, Drug and Medical Device | Not stated |
| Kevin Sforza | Sidley | Not stated | Food, Drug and Medical Device | Not stated |
| Dan Altman | Sidley | Not stated | Tax | Not stated |
| Alvin Wang | Sidley | Not stated | Tax | Not stated |
| Matt Dolan | Sidley | Not stated | Securities and Shareholder | Not stated |
| Corey Perry | Sidley | Not stated | Employee Benefits and Executive Compensation | Not stated |
| Asher Rubin | Sidley | Not stated | Technology and Life Sciences Transactions | Not stated |
| Adriana Tibbits | Sidley | Not stated | Technology and Life Sciences Transactions | Not stated |
Stated terms
- Stated value
- USD 550m (US$550 million)
- What the figure measures
- Issue size
- Client
- Immunovant, Inc.Issuer
- Counterparties
- Leerink Partners (Underwriters)